logo
#

Latest news with #OneHealthTrust

New Study Reveals Widespread Drug Resistance Across 14 African Countries
New Study Reveals Widespread Drug Resistance Across 14 African Countries

Zawya

time7 days ago

  • Health
  • Zawya

New Study Reveals Widespread Drug Resistance Across 14 African Countries

Results from a newly published study highlight the growing spread of drug resistance across 14 African countries, underscoring the urgent need to strengthen laboratory testing, data systems, and health planning to tackle hard-to-treat infections. The study, known as the Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP), is the largest of its kind ever conducted in Africa. It was led by a coalition including the Africa Centres for Disease Control and Prevention (Africa CDC), the African Society for Laboratory Medicine (ASLM), One Health Trust, and other regional partners. Researchers reviewed more than 187,000 test results from 205 laboratories, collected between 2016 and 2019 across Burkina Faso, Eswatini, Ethiopia, Ghana, Kenya, Malawi, Mali, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe. Drug resistance occurs when bacteria change in ways that make antibiotics—medicines used to treat infections—less effective. This means that common infections become harder to treat, more expensive to manage, and more likely to spread. The study examined bacteria that commonly cause serious illness, such as E. coli, Staphylococcus aureus, and Klebsiella pneumoniae. One of the most concerning findings was that resistance to a powerful group of antibiotics, known as third-generation cephalosporins, was especially high in Ghana and Malawi. In six countries, more than half of the Staphylococcus aureus samples were resistant to methicillin—an antibiotic commonly used in hospitals. In Nigeria and Ghana, resistance levels exceeded 70%. The research also showed that some groups are more likely to have drug-resistant infections. People over the age of 65 were 28 per cent more likely to have resistant infections than younger adults. Patients already admitted to hospitals had a 24 per cent higher risk, likely due to increased exposure to antibiotics. Previous use of antibiotics was also linked to higher resistance. However, the study also revealed serious gaps. Fewer than 2 per cent of health facilities were equipped to test for bacterial infections, and only 12 per cent of drug resistance records were linked to patient information. Without this kind of data, it is more difficult for health officials to understand how and why resistance is spreading. The quality of data varied between countries. Senegal had the strongest systems, while Sierra Leone struggled with data collection. Many laboratories still use handwritten records, and most lack reliable digital systems. Supported by the UK's Fleming Fund and the US Centers for Disease Control and Prevention (CDC), the study calls on governments to make drug resistance a national priority by investing in better laboratories, routine testing, and stronger digital systems. Without action, the threat of drug resistance could reverse decades of health and development gains. 'For African countries, AMR remains a wicked and complex problem, leaving countries with a million-dollar question: 'Where do we start from?' This study brings to light groundbreaking AMR data for African countries. We must act now—and together—to address AMR,' said Dr Yewande Alimi, the One Health Unit Lead at Africa CDC. Distributed by APO Group on behalf of Africa Centres for Disease Control and Prevention (Africa CDC).

Covid-19 resurgance: What is JN.1 strain and where is it active?
Covid-19 resurgance: What is JN.1 strain and where is it active?

The National

time21-05-2025

  • Health
  • The National

Covid-19 resurgance: What is JN.1 strain and where is it active?

The JN.1 strain of Covid-19 is spreading through South-east Asia, with health authorities in Hong Kong, Singapore, China and Thailand urging people to get new booster vaccinations. Here's everything we know about this strain of Covid that is considered more contagious than other variants: The virus is considered active in Hong Kong, with the city state reporting 31 severe cases in the first week of this month. In Singapore, the Health Ministry said the number of Covid cases jumped 28 per cent to 14,200 in the week ending May 3, with the number of people being admitted to hospital rising by about 30 per cent. The picture is similar in Thailand, where Covid cases reached 33,030 last week, doubling from the 16,000 cases reported the week previously. Covid cases are also rising in China, with positivity rates among outpatient and emergency flu-like cases increasing from 7.5 per cent to 16.2 per cent since March, the Centre for Disease Control and Prevention said. The JN.1 Covid variant is a descendant of the BA. 2.86 strain that carries more than 30 mutations in the spike protein. 'Covid is with us permanently and we have to be vigilant about new strains like JN.1, a sub-lineage of BA. 2.86 Omicron, that appears correlated with increase in hospitalisation for respiratory illness,' Ramanan Laxminarayan, president of health research organisation One Health Trust, previously told The National. The World Health Organisation (WHO) has designated JN.1 as "variant of interest", though not yet a "variant of concern." The WHO's definition states that a variant of interest has 'genetic changes that are predicted or known to affect virus characteristics such as transmissibility, virulence, antibody evasion, susceptibility to therapeutics and detectability'. So JN.1 is more contagious than other Covid strains at this time. It is also 'identified to have a growth advantage over other circulating strains in more than one WHO region with increasing relative prevalence alongside increasing number of cases over time, or other apparent epidemiological impacts to suggest an emerging risk to global public health'. The first case of JN.1 was recorded in the US in September 2023. JN.1 has not shown any signs of greater severity than other Covid strains but it is more contagious.

JN.1 Covid variant: What is it and where is it active?
JN.1 Covid variant: What is it and where is it active?

The National

time20-05-2025

  • Health
  • The National

JN.1 Covid variant: What is it and where is it active?

The JN.1 strain of Covid-19 is spreading through South-east Asia, with health authorities in Hong Kong, Singapore, China and Thailand urging people to get new booster vaccinations. Here's everything we know about this strain of Covid that is considered more contagious than other variants: The virus is considered active in Hong Kong, with the city state reporting 31 severe cases in the first week of this month. In Singapore, the Health Ministry said the number of Covid cases jumped 28 per cent to 14,200 in the week ending May 3, with the number of people being admitted to hospital rising by about 30 per cent. The picture is similar in Thailand, where Covid cases reached 33,030 last week, doubling from the 16,000 cases reported the week previously. Covid cases are also rising in China, with positivity rates among outpatient and emergency flu-like cases increasing from 7.5 per cent to 16.2 per cent since March, the Centre for Disease Control and Prevention said. The JN.1 Covid variant is a descendant of the BA. 2.86 strain that carries more than 30 mutations in the spike protein. 'Covid is with us permanently and we have to be vigilant about new strains like JN.1, a sub-lineage of BA. 2.86 Omicron, that appears correlated with increase in hospitalisation for respiratory illness,' Ramanan Laxminarayan, president of health research organisation One Health Trust, previously told The National. The World Health Organisation (WHO) has designated JN.1 as "variant of interest", though not yet a "variant of concern." The WHO's definition states that a variant of interest has 'genetic changes that are predicted or known to affect virus characteristics such as transmissibility, virulence, antibody evasion, susceptibility to therapeutics and detectability'. So JN.1 is more contagious than other Covid strains at this time. It is also 'identified to have a growth advantage over other circulating strains in more than one WHO region with increasing relative prevalence alongside increasing number of cases over time, or other apparent epidemiological impacts to suggest an emerging risk to global public health'. The first case of JN.1 was recorded in the US in September 2023. JN.1 has not shown any signs of greater severity than other Covid strains but it is more contagious.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store